SCHEMBL30922527

SCHEMBL30922527

OC/C=C\c1c(Cl)cc2c(cnn2C2CCCCO2)c1Br

nearest known ligand 0.39

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 1/20 0.39
▸ RXRB P28702 1/20 0.39
▸ RXRG P48443 1/20 0.39
▸ CYP4F2 P78329 2/20 0.33
▸ CYP4A11 Q02928 2/20 0.33
▸ DGAT2 Q96PD7 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ WDR5 P61964 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31642907 0.90 RXRA (0.37) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL31642671 0.88 RXRA (0.38) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL25373206 0.86 RXRA (0.37) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL30542408 0.86 RXRA (0.37) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL25373201 0.86 RXRA (0.37) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL30922807 0.85 RXRA (0.36) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL30922889 0.85 RXRA (0.37) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL30922407 0.85 ALDH1A1 (0.39) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL31127808 0.84 RXRA (0.38) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL30922960 0.83 RXRA (0.33) RXRARXRBRXRGDGAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4598921-A1 MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE Amgen Inc. (US) 2025-08-13 — — EP disclosed
WO-2025136346-A1 INDAZOLE CONTAINING COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2025-06-26 — — WO disclosed
WO-2024107686-A1 MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE AMGEN INC. (US) 2024-05-23 — — WO disclosed
Send feedback